Does semaglutide cause muscle loss?

Short answer: semaglutide drives large weight loss, and any large weight loss takes some lean tissue with it. But the body-composition data on semaglutide show fat mass falling much faster than lean mass, so the share of the body that is lean tissue tends to rise over a course of treatment, not fall^[2]. The honest framing is not that semaglutide melts muscle, but that it removes a lot of weight and a smaller, fairly predictable slice of that weight is fat-free mass rather than fat.

Some numbers first. In STEP-1, the pivotal obesity trial, semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks against 2.4% on placebo, roughly 15.3 kg versus 2.6 kg^[1]. Losing that much weight is exactly the situation where the muscle question matters, because fat is not the only tissue that comes off. The useful question is not whether any lean mass is lost, but how much, and whether it is out of proportion to the fat.

What the semaglutide body-composition data show

The most detailed semaglutide-specific picture comes from the SEMALEAN study, published in Diabetes, Obesity and Metabolism in 2026, which followed 106 adults with obesity through 12 months of treatment using DXA scans (dual-energy X-ray absorptiometry, the standard way to split body weight into fat and fat-free mass)^[2]. Total fat mass fell 14.3% at 7 months and 18.9% at 12 months. Lean mass dropped by about 3 kg early on and then stabilised, so the proportion of the body made up of lean tissue rose rather than fell.

The functional readouts pointed the same way. Handgrip strength, a practical measure of muscle function, improved by 4.1 kg at 12 months, and the share of participants meeting the definition for sarcopenic obesity fell from 49% at baseline to 33%^[2]. That pattern holds when you pool the wider evidence. A 2025 meta-analysis in the same journal found that GLP-1 receptor-based agonists produced a mean fat-mass reduction of 2.25 kg and a lean-mass reduction of 1.02 kg against controls, but the change in lean mass as a percentage of body weight was comparable to people not on the drug^[4]. In plain terms, fat loss predominated, and the drug did not shift the fat-to-lean ratio in a worse direction.

Why 'muscle loss' is a slippery term here

Two things get blurred in the question. First, lean mass and muscle are not the same thing. DXA measures fat-free mass, which includes water, organ tissue, and connective tissue, not only skeletal muscle, so a fall in lean mass on a scan overstates how much actual muscle is gone. Second, some fat-free mass loss accompanies almost any meaningful weight loss, whether it comes from diet, surgery, or a drug. A 2024 review of lean-mass changes across GLP-1-based therapies found the lean-mass figure ranges widely between studies, from about 15% or less of total weight lost at one end to 40% or even 60% at the other^[3].

The same review argued that most of this reduction looks adaptive, meaning it tracks the amount of weight lost and the person's age and health rather than signalling a drug-specific attack on muscle^[3]. Larger total weight loss brings larger absolute lean-mass loss, which is one reason the headline muscle-loss fears often run ahead of what the body-composition data support. The same logic applies to the dual agonist tirzepatide and the triple agonist retatrutide: for that comparison, see whether retatrutide causes muscle loss.

The levers that preserve muscle

One point the weight-loss literature agrees on is that the muscle coming off during weight loss responds to the usual levers. In a randomised trial of older adults losing weight through diet, those who added resistance exercise, or combined resistance and aerobic training, lost about 2% to 3% of their lean mass, against 5% in the aerobic-only group, at the same 9% body-weight reduction^[5]. Resistance training and adequate protein intake are the standard tools for holding on to lean mass while losing fat, and dedicated muscle-sparing drug combinations are in development. None of that is specific to semaglutide, and none of it is a reason to source the drug outside a prescription.

Where this lands

On the evidence available today, semaglutide does not appear to cause disproportionate muscle loss relative to the weight it removes. Fat mass falls faster than lean mass, and functional measures such as grip strength can improve. The lean tissue that does come off is best protected with resistance training and protein, not by avoiding treatment. If you are weighing this up, remember that semaglutide is a prescription-only medicine everywhere we cover: see the semaglutide regulation status for where it stands, and talk to a clinician before making any decision about starting, stopping, or changing a course.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.